09/30/2025
The current frontier of cancer vaccines
The three most prominent forms of cancer vaccine are intravesical BCG live, sipulecel-T, and T-VEC vaccines. Each exhibits unique kinetics when introduced to the body and will target aberrantly expressed proteins. A notable example of an aberrant protein could be neoantigens, possessing the ability to exchange throughout different cancer cell lines, resulting in harmful antigen cascades.
Bacillus of Calmette and Guerin (BCG) strains of Mycobacterium Bovis are employed as attenuated cancer vaccines, made potent through the high colony turnover and subsequent serial dilution assays. Sipuleucel-T vaccines (developed by Dendreon Corporation) are used in treating asymptomatic metastatic prostate cancer, made possible after a decade of immunological research and 13 years of clinical trials.
Representing the first approved cancer vaccine, this therapeutic encompasses an excellent risk-to-benefit ratio and is easily used in conjunction with other, more aggressive treatment measures. Finally, Talimogene laherparepvec (T-VEC) vaccines are immunotherapies that treat melanoma skin cancer that has metastasized and spread throughout the lymph nodes and soft tissues.
How cancer vaccines operate
Cancer vaccines are charged with stimulating the long-term immune responses that are triggered by host T-cells. This therapeutic is in its infancy compared to more traditional forms of treatment and is thus being used in C57BL/6 mice, Sprague-Dawley rats, and other murine models. This is performed to test its properties within tumor microenvironments and its properties of immunosuppression. The tumor’s microenvironment consists of many elements, including immunosuppressive markers, altered extracellular matrices, and solubility factors. These all go to alter the metastatic ability of the tumor and, consequently, are prime targets for cancer vaccines.
